Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be ...

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Lilly’s momentum isn’t just about its successful clinical results, though. It’s also about the company’s constant iteration ...

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and ...

Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more ...

By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss ...

The drugmaker unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows. It’s ...

Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity ...